HOME > About Us > Executive Officers

RIBOMIC, Inc. is a leading company in the world developing innovative aptamer therapeutics.

Executive Officers

Director

Yoshikazu Nakamura President and Chief Executive Officer
Yoshikazu Nakamura
President and Chief Executive Officer
Yoshikazu Nakamura is President and Chief Executive Officer of Ribomic Inc. He is Professor Emeritus of The University of Tokyo and he has a Ph.D. from Kyoto University.
Throughout his academic career at The University of Tokyo and entrepreneurial career at Ribomic, Dr. Nakamura has been engaged in research on RNA. He discovered a novel biological concept “molecular mimicry between protein and RNA” in 2000, which provided the basis for RIBOMIC’s R&D activities.
He founded the company in 2003 and served as Director and Chief Science Officer since 2005. He was appointed President and CEO in 2012 upon his retirement from The University of Tokyo. In the same year, he was named Professor Emeritus of the University for his 34 years of work at The University of Tokyo Institute of Medical Science (IMSUT).
He joined IMSUT in 1977 after getting his Ph.D. (his PhD thesis was molecular genetics). At IMSUT, he was named Assistant Professor in 1978, Associate Professor in 1986 and Professor in 2000, the last of which positions he kept until his retirement in 2012.
He conducted research as a postdoctoral fellow at the University of Utah from 1980 to 1981. He was appointed US NIH NCI Expert in 1984, invited as a visiting research fellow at French National Institute IBPC (Institut de Biologie Physico-Chimique) from 1984 to 1988, and named Consultant at US NIH NCI-Frederick PRI from1985 to 1988.
He has also served the scientific community as Vice President of A-IMBN (Asian-Pacific International Molecular Biology Network) since 2003, and President of the RNA Society of Japan from 2006 to 2010.
Masayuki Miyazaki Board Director, Business Administration Department
Masayuki Miyazaki
Board Director,
Administration Division
Masayuki Miyazaki joined Ribomic in 2008 as General Manager, Business Administration Department and was named Board Director in 2009. Prior to working at Ribomic, he worked for SHINSEIDO Co., Ltd., initially in charge of system development and then managed Sales and Finance.
Subsequent to the company’s successful IPO, in which he was a major contributor, he was named Chief Financial Officer of Shinseido with responsibilities for negotiations with audit firms and financial institutions as well as developing management and financial strategies.
Before SHINSEIDO, he worked at Olivetti, Japan on development of application software for computer systems. He is a graduate of Tokyo University of Education.
Masatoshi Fujiwara Board Director, Research & Development Division
Masatoshi Fujiwara
Board Director,
Research & Development Division
Masatoshi Fujiwara has served as RIBOMIC’s General Manager, Developmental Research Department since 2005 and Corporate Officer, Developmental Research Department since 2007. Prior to joining Ribomic, He worked on research and development of medicinal drugs at Toyo Soda Manufacturing Co., Ltd (now Tosoh Corporation) and Nippon Glaxo Ltd. (now Glaxo SmithKline K.K.). He was awarded Doctor of Medicine by Fukushima Medical University in 2001. He is a specialist in pharmacology and safety in pre-clinical studies.
Hirofumi Morikawa Independent Board Director (outside*)
Hirofumi Morikawa
Independent Board Director (outside*)
Hirofumi Morikawa was appointed an independent member of the Board (outside*) in 2015. He is a licensed social and labor insurance consultant and consults for a number of medical and social welfare organizations.
He obtained his Ph.D. in Health and Welfare Management from International University of Health and Welfare Graduate School in 2010. He had worked for Lawson Inc. as Managing Director of the Kanto area office, Administration officer of Sales Head office before his appointment as Statutory Auditor for a group of DAIEI department stores, NAKAGO (Fukushima, Aizu and Sakata). His earlier career includes working for NISSIN FOODS HOLDINGS Co., Ltd. He is a graduate of Kansai University.

*an “outside” director is a Japanese notion which signifies someone who has had no affiliation with the company, neither in person nor in corporate terms, prior to joining the company.
Toshiaki Nishihata Independent Board Director (outside*)
Toshiaki Nishihata
Independent Board Director (outside*)
Toshiaki Nishihata joined RIBOMIC Inc. in 2015 as Adviser and was named Independent Board Director (outside*) in 2016.
After winning Ph.D.in Pharmaceutics in 1978 he was named Associate Professor by The University of Kansas. He then joined Upjohn Pharmaceuticals Ltd. (now Pfizer Inc.) in 1988 and took part in development projects including clinical research. He joined Santen Pharmaceutical Co., Ltd. in 1996 where he led the company’s global ophthalmological business as Member of the Board and Head of Research and Development. He is well acquainted with quality management in medicine and was a member in writing the Japanese GMP Guideline.

*an “outside” director is a Japanese notion which signifies someone who has had no affiliation with the company, neither in person nor in corporate terms, prior to joining the company.

Auditor

Motohiko Fujii Independent Auditor (full time and outside*)
Motohiko Fujii
Independent Auditor (full time and outside*)
Motohiko Fujii joined Ribomic as Full-time Independent Statutory Auditor (full time and outside*) in 2010.
Upon graduation from Keio University, he joined Mitsubishi Trust and Banking Corporation (now Mitsubishi UFJ Trust and Banking Corporation), and worked mainly in the Securities Department and International Department. His overseas assignments included New York, Panama, and London. In London, he was Managing Director of the bank’s securities subsidiary and successfully established securities business of the company. After returning to Tokyo, he worked in the International Planning Department and led the bank to obtain its first AAA rating.
Following his mandatory retirement from the bank, he joined ZYPRO Corporation, which sells automotive parts. As director of general administration, he successfully led the company in its IPO. He was then appointed full-time auditor, a position he kept until he joined Ribomic in 2010.

*an “outside” auditor is a Japanese notion which signifies someone who has had no affiliation with the company, neither in person nor in corporate terms, prior to joining the company.
Masaaki Takagi Auditor
Masaaki Takagi
Auditor
Masaaki Takagi joined Ribomic in 2006 and successfully led the second fund-raising of the company. He was appointed Board Director in charge of finance in 2007 and then appointed corporate auditor.
His career prior to RIBOMIC was in finance, working for Morgan Guaranty Trust Company in New York and Los Angels, Morgan Guaranty Limited, Salomon Brothers and Robert Fleming in London and HSBC in Tokyo. He was named General Manager in charge of Visa International Japan in 2000. He holds an MBA from Stanford University and a BA from Yale University.
Yutaka Yabe Auditor (Outside*)
Yutaka Yabe
Auditor (Outside*)
Yutaka Yabe has served as RIBOMIC’s Auditor (outside*) since 2010. After passing Part II of the Certified Public Accountant Examination in 1964, he joined a CPA firm, Yasumori Office. He was registered as a CPA in 1968. He is a graduate of Hosei University.
He established his own CPA firm, Yabe Office in 1972. He also established Yasumori Audit Corporation and was appointed representative director in 1982 and was appointed CEO in 2003. Until his retirement from the Corporation in 2009, he was in charge of IPO and auditing of listed companies.

*an “outside” auditor is a Japanese notion which signifies someone who has had no affiliation with the company, neither in person nor in corporate terms, prior to joining the company.